Drug treatment of primary insomnia: A meta-analysis of polysomnographic randomized controlled trials

CNS Drugs

Volumn 28, Issue 9, 2014, Pages 799-816

  Winkler, Alexander ^a   Auer, Charlotte ^a   Doering, Bettina K ^a   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIGESTAGEN; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DOXEPIN; HORMONE; MELATONIN RECEPTOR AGONIST; NARCOTIC AGENT; NEUROPEPTIDE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

DATA SYNTHESIS; DRUG EFFICACY; HUMAN; LATENT PERIOD; LOW DRUG DOSE; META ANALYSIS; POLYSOMNOGRAPHY; PRIMARY INSOMNIA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; PATHOPHYSIOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

HUMANS; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84919914304     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0198-7     Document Type: Review

References (74)

1. Morin CM, Savard J, Ouellet M-C. Nature and treatment of insomnia. USA: Wiley; 2013. p. 318-39.
2. Leger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin. 2008;24(1):307-17.
3. Roth T, Coulouvrat C, Hajak G, Lakoma MD, Sampson NA, Shahly V, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and related health problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry. 2011;69(6):592-600.
4. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-50.
5. McCrae CS, Lichstein KL. Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med Rev. 2001;5(1):47-61. doi: 10.1053/smrv.2000.0146.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.; text rev. Washington: APA; 2000.
8. Buysse DJ. Insomnia. JAMA. 2013;309(7):706-16.
9. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.
10. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169-73. doi: 10.1136/bmj.38623.768588.47.
11. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol Clin Exp. 2004;19(5):305-22. doi: 10.1002/hup.594.
12. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159(1):5-11.
13. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J. 2000;162(2):225-33.
14. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278(24):2170-7.
15. Fernandez-San-Martin M, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505-11.
16. Liu J, Wang LN. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract. 2012;66(9):867-73. doi: 10.1111/j.1742-1241.2012.02987.x.
17. Baldwin D. Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence. J Psychopharmacol. 2005;19(2):134-5. doi: 10.1177/0269881105051991.
18. JARS. Reporting standards for research in psychology: Why do we need them? What might they be? Am Psychol. 2008;63(9):839-51. doi: 10.1037/0003-066X.63.9.839.
19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354(9193):1896-900.
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-12. doi: 10.1016/j.jclinepi.2009.06.005.
21. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12.
22. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the potsdam consultation on meta-analysis. J Clin Epidemiol. 1995;48(1):167-71.
23. Morin CM. Measuring outcomes in randomized clinical trials of insomnia treatments. Sleep Med Rev. 2003;7(3):263-79. doi: 10.1053/smrv.2002.0274.
24. Baglioni C, Regen W, Teghen A, Spiegelhalder K, Feige B, Nissen C, et al. Sleep changes in the disorder of insomnia: a meta-analysis of polysomnographic studies. Sleep Med Rev. 2014;18(3):195-213. doi: 10.1016/j.smrv.2013.04.001.
25. Glass G. Primary, secondary and meta-analysis of research. Health Educ Res. 1976;5:3-8.
26. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
27. Borenstein M, Hedges L, Higgins J, Rothstein H. Comperhensive meta-analysis, version 2. 2nd ed. Engelwood: Biostat Inc.; 2005.
28. Hedges LV, Olkin I. Nonparametric estimators of effect size in meta-analysis. Psychol Bull. 1984;96(3):573-80. doi: 10.1037/0033-2909.96.3.573.
29. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates Inc; 1988.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
31. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester: Wiley; 2009.
32. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-63. doi: 10.1111/j.0006-341X.2000.00455.x.
33. Rosenthal R. Meta-analytic procedures for social research. Newbury Park: Sage Publications; 1993.
34. Johnson BT, Eagly AH. Quantitative synthesis of social psychological research. In: Reis HT, Judd CM, editors. Handbook of research methods in social and personality psychology. London: Cambridge University Press; 2000. p. 496-528.
35. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1-3):1-8. doi: 10.1016/j.jad.2009.01.029.
36. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression - variable, substantial, and growing. JAMA. 2002;287(14):1840-7. doi: 10.1001/jama.287.14.1840.
37. Xu ZQ, Jiang XJ, Li W, Gao D, Li XJ, Liu J. Propofol-induced sleep: efficacy and safety in patients with refractory chronic primary insomnia. Cell Biochem Biophys. 2011;60(3):161-6. doi: 10.1007/s12013-010-9135-7.
38. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32(3):351-60.
39. Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 2012;35(11):1551-7. doi: 10.5665/sleep.2208.
40. Riemann D, Nissen C. Substanzinduzierte Schlafstörungen und Schlafmittelmissbrauch. Bundesgesundheitsbl. 2011;54(12):1325-31. doi: 10.1007/s00103-011-1374-2.
41. Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006;20(4):397-403. doi: 10.1111/j.1472-8206.2006.00415.x.
42. Morin AK, Willett K. The role of eszopiclone in the treatment of insomnia. Adv Ther. 2009;26(5):500-18. doi: 10.1007/s12325-009-0026-5.
43. Mitchell M, Gehrman P, Perlis M, Umscheid C. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13(1):40.
44. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295(24):2851-8. doi: 10.1001/jama.295.24.2851.
45. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med. 2004;164(17):1888-96. doi: 10.1001/archinte.164.17.1888.
46. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281(11):991-9.
47. Wu RG, Bao JF, Zhang CA, Deng J, Long CL. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychother Psychosom. 2006;75(4):220-8. doi: 10.1159/000092892.
48. McClusky H, Milby J, Switzer P, Williams V, Wooten V. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry. 1991;148:121-6.
49. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-7. doi:118919.
50. Buckley T, Duggal V, Schatzberg AF. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. J Clin Sleep Med. 2008;4(3):235-41.
51. Fleming J, Moldofsky H, Walsh JK, Scharf M, Nino MG, Radonjic D. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Investig. 1995;9(6):303-313.
52. Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62(6):453-63. doi: 10.4088/JCP.v62n0609.
53. Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res. 1993;21(6):306-22.
54. Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33(11):1553-61.
55. Krystal AD, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433-42. doi: 10.5665/sleep.1294.
56. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24(5):239-49. doi: 10.1097/YIC.0b013e32832e9b08.
57. McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. 2006;22(9):1633-42. doi: 10.1185/030079906x112741.
58. Monti JM, Alvarino F, Monti D. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia. Sleep. 2000;23(8):1075-84.
59. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry. 1994;27(4):166-75. doi: 10.1055/s-2007-1014298.
60. Monti JM, Monti D, Estevez F, Giusti M. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol. 1996;11(4):255-63. doi: 10.1097/00004850-199612000-00007.
61. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28(11):1465-71.
62. Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Ruether E, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Trimipramin bei primaerer Insomnie: ergebnisse einer polysomnographischen kontrollierten Doppel-Blind-Studie. Pharmacopsychiatry. 2002;35:165-74.
63. Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008.
64. Roth T, Wright KP, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep. 2006;29(3):335-41.
65. Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol. 1997.
66. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192-9.
67. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers - a pilot-study. Pharmacopsychiatry. 1994;27(4):147-51. doi: 10.1055/s-2007-1014295.
68. Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med. 2006;2(1):35-41.
69. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry. 2008;16(1):44-57. doi: 10.1097/JGP.0b013e3181256b01.
70. Walsh JK, Vogel GW, Scharf M, Erman M, Erwin CW, Schweitzer PK, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1(1):41-9. doi: 10.1016/s1389-9457(99)00006-4.
71. Ware J, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol. 1997;20(2):116-25. doi: 10.1097/00002826-199704000-00002.
72. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3(5):495-504.
73. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;. doi: 10.1185/174234304X15174.
74. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12(3):191-204. doi: 10.1038/nrd3923.